Ninety patients in the maintenance therapy phase of the Pittsburgh Study of Maintenance Therapies in Recurrent Depression were studied to determine possible relationships between the type of therapy (imipramine versus no drug) and the level of sexual functioning. The level of sexual functioning was determined by a composite subscale score of the Social Adjustment Scale which assessed (1) current level of enjoyment and interest in sex; (2) change in interest; (3) current frequency of sexual intercourse; (4) change in frequency; and (5) pain and/or difficulty reaching orgasm. Loss of libido was assessed by both the Hamilton KEY WORDS: Imipramine; Sexual dysfunctions; Maintenance; Depression; Tricyclics
Research examining the side-effects of antidepressants has effectively documented the potential negative effects such agents may have on patients suffering from acute major depression (Jefferson 1975; Cassem 1982; Rabkin et al. 1985; Pollack and Rosenbaum 1987; . It would appear, however, that those en rolled in long-term maintenance therapy may ex perience fewer such effects, at least in the area of weight gain (Frank et al. 1992) . Despite anecdotal evidence sug gesting that sexual side effects are frequent and a com-Rating Scale for Depression and the SeL-90. Logistic regression analysis revealed no relationship between treatment with active imipramine and sexual functioning for the total group, or for females alone. Analysis of males alone revealed a decreased interest in sex among those treated with imipramine, but no significant differences in frequency or problems. The implications for maintenance pharmacotherapy and the costibenefit ratio of unacceptable side effects versus drug efficacy are discussed. lNeuropsychopharmacology 11: 21-27, 1994J mon reason for drug discontinuation or noncompliance, the number of controlled studies of the effects of an tidepressant medication on sexual function is limited. Kolodny et al. (1979) state that approximately 5% of depressed patients treated with tricyclics experience a paradoxical sexual response involving a continued dis ruption of sexual function despite clinical amelioration of other symptoms of depression. A comprehensive re view of the sexual side effects of psychiatric drugs (Se graves 1988) documents 33 case reports of sexual im pairment due to antidepressant agents. Most of these descriptions (22 out of 33 patients) are men experienc ing erectile dysfunction and ejaculatory failure as a re sult of tricyclic medications (Greenberg 1965; Simpson et al. 1965; Gross 1982; Schwarcz 1982; Yassa 1982; Nininger 1987; Price and Grunhaus 1990) .
A double-blind study conducted by Harrison et al. (1985 Harrison et al. ( , 1986 ) examined the effects of imipramine and phenelzine on sexual function. Both drugs decreased the frequency of masturbation, and phenelzine de-creased the number of sexual thoughts. Kowalski and colleagues (1985) examined the effects of amitriptyline and mianserin on nocturnal penile tumescence. The results suggest that both compounds decrease the mag nitude and the frequency of nocturnal erections. It should be noted, however, that the sample used was a nonpsychiatric population.
Only one placebo-controlled clinical trial has been identifIed that specifIcally evaluates the effect of a tricy clic (clomipramine) on the sexual functioning of women (Monteiro et al. 1987 ). The population studied were all seeking treatment for symptoms of obsessive-compul sive disorder, and not depression. Twenty-nine per cent of the women in the clomipramine treatment group reported both decreased interest in sex (attributing to diffIculty achieving orgasm) and problems with lubri cation. Forty-three percent described reduced sexual sensation, and 71% were anorgasmic. The generaliza tion of these findings for women being treated with depression is questionable because the neurological and affective differences between obsessive-compulsive dis order and major depression are marked.
Several case reports have documented sexual dys function in depressed women, due not to their affec tive illness, but due to their treatment with tricyclics. Price et al. (1986) describe a patient experiencing anor gasmia from treatment with imipramine. Quirk and Einarson (1982) report that two women (ages 24 and 30) both having depression and features of obses sive-compulsive disorder became completely anorgas mic upon treatment with clomipramine. Riley and Riley (1986) similarly describe two depressed women who became anorgasmic due to treatment with clomipra mine, and one woman who experienced similar side effects resulting from treatment with imipramine. Sov ner (1983) and Shen (1982) report anorgasmia in de pressed women due to treatment with imipramine and amoxapine, respectively. Sovner (1984) also reported that nortriptyline, an antidepressant which affects serotonergic activity, produced anorgasmia.
These potential negative side-effects of treatment with tricyclics may increase the wariness of men and women experiencing depression with regard to the efficacy of these medications, and this may diminish the adherence to prescribed treatment regimens. This increased wariness may also reduce the willingness of a patient to continue treatment with maintenance phar macotherapy, even though this has been found to signifIcantly reduce the chance of recurrence Kupfer et al. 1992; Frank et al. 1993) . There fore, a better understanding of the impact of main tenance tricyclic therapy on sexual function is clearly warranted. The present report focuses on ongoing sex ual difficulties in patients randomly assigned to main tenance treatment with imipramine in the range of 200 NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 mg in comparison to those assigned to placebo or to non pill conditions.
METHODS
The patients included in the present report were receiv ing treatment in the Pittsburgh Study of Maintenance Therapies in Recurrent Depression ). All subjects were between ages 21 and 65, and entered the program in their third or greater episode of definite major depressive disorder, according to Research Di agnostic Criteria (RDC) (Spitzer et al. 1978) . In addi tion, all patients were required to have had at least one other major depressive episode during the prior 2.5 years, one additional lifetime major depressive episode, and at least a 10-week period of remission between the index episode and the immediately previous episode. These criteria for patient selection were utilized to yield a study group at high risk for recurrence. All previous episodes must have required psychiatric treatment or must have resulted in significant functional impairment. Patients with a recent history of nonaffective Axis I psy chiatric disorder were excluded, as were those who had significant medical histories. Patients meeting full RDC for borderline or antisocial personality disorder were also excluded from the study, although patients with other Axis II disorders were not. Following a minimum two-week drug-free wash-out period, each patient un derwent a comprehensive independent assessment to reevaluate the severity of depression. A Raskin Severity of Depression score (Raskin et al. 1969 ) of seven or greater, and a Hamilton Rating Scale for Depression (HRSD) score (Hamilton 1960 ) of 15 or greater con stituted the severity criteria for inclusion in this protocol.
All subjects then received the same short-term treat ment regimen consisting of a combination of imipra mine hydrochloride (150 mg to 300 mg) and interper sonal psychotherapy (IPT) (KIerman et al. 1984) . Treatment sessions were scheduled weekly for 12 weeks, then biweekly for 8 weeks, and then monthly. At whatever point in this short-term treatment regimen the patient maintained an HRSD score of less than or equal to five for three consecutive weeks, a second bio logical and psychosocial evaluation was completed. Pa tients then continued to receive combined treatment for an additional 17 weeks, during which both HRSD and Raskin scores, and imipramine dosages were re quired to remain stable. A third evaluation was then conducted. After that, patients were randomly assigned to one of the five maintenance treatments: (1) Table 2 .
Statistical Methods
Ordinal logistic regression analysis was used to deter mine if sexual dif:&culties during maintenance treatment were related either to being on active medication or to experiencing subsyndromal symptoms of depression.
Analysis was conducted to determine if (1) an associa tion existed between treatment with imipramine and the level of sexual functioning as determined by the SAS composite score and (2) an association existed between HRSD-l6-item total (measured at six months into main tenance) and the level of sexual functioning as deter mined by the SAS composite score.
Pearson correlations were used to test the associa tion between the Hamilton loss-of-libido item score and the score for the remaining 16 items of the HRSD score. Correlations were also used to examine the relation ships between the SAS loss of libido item and the total Hamilton score. Analyses were conducted on the entire sample of ninety subjects and separately on the group of female (n = 71) and male (n = 19) patients. Kruskal-Wallis anal ysis of the individual variables of the sexual function ing composite score, and the other measures of sexual functioning were performed for the total group, and for the two subgroups.
RESULTS

Total Group
Logistic regression analysis failed to show any statisti cally signilicant relationship between active imipramine treatment and the level of sexual functioning (n = 90, P = .75). Similarly, no association was found among drug treatment, level of depression, and level of sex ual functioning (p = .18). As can be noted in Table 2 the drug group and the non-drug group for the in dividual sexual functioning variables.
Pearson correlation analysis showed a signiftcant relationship between the SCL-90 loss-of-libido item and a higher score on the HRSD-16 for the group not treated with active antidepressant (r = 0.30, P < .04) as well as for the group treated with imipramine (r = 0.43, P < .006).
A signiftcant correlation was discovered between the Hamilton loss-of-libido item and the remaining 16 Hamilton scale items among those subjects not treated with medication (r = 0.42, p< .003); however, no rela tionship was discovered between these two variables for those patients in the active drug group (r = 0.17, P = .28).
Females
Logistic regression analysis revealed no association be tween treatment with imipramine and the level of sex ual functioning in female patients (n = 71, P = .50). Similarly, no relationship was found between drug treatment, the 16-item HRSD scores, and a decreased level of sexual functioning. Table 3 lists the range of composite SAS scores for female subjects. As can be noted in Table 2 , Kruskal-Wallis analysis discovered no diff erences between the drug and the non-drug group for the other variables of sexual functioning.
Similar to the analysis of the entire sample, there was a statistically signmcant correlation for both the drug (r = 0.360, P < .05) and the non-drug (r = 0.409, A second limitation of the present investigation is its focus on assessment of sexual function at a single point rather than throughout the maintenance phase.
The decision was made to examine a single time point six months after random assignment to the various maintenance treatment conditions in order to maximize the number of subjects in both drug and nondrug groups available for analysis, while still allowing suffi cient time for any effects of prior acute and continua tion drug treatment to dissipate. Had we examined data later in the maintenance phase (e.g., at one year or 18 months), power would have been markedly reduced and the groups would have become much more un-balanced as a result of the number of recurrences in the nonmedication conditions. Regardless of these limitations, we believe that these results demonstrate the relatively benign effects of long-term antidepressant therapy with respect to sex ual diffi culties. In the analysis of the total group, while logistic regression failed to fInd a relationship between either drug treatment status or level of depression and sexual functioning, correlational analysis suggested a relationship between the level of depression and the loss of libido. The relationship appeared to be more con sistent in those patients treated without medication, ap pearing for both the SCL-90 and the Hamilton loss-of libido items. As females comprised the majority of the study population, it is not surprising that the findings for the female-only group parallel those for the total group.
Interpretation of the data on the males is problem atic because of the relatively small number of subjects. Logistic regression failed to prove a relationship be tween drug treatment and composite SAS score. The power for this analysis, however, was low. A Kruskal Wallis test revealed a diff erence between drug-treated and nondrug-treated males only regarding sexual in terest among the five SAS variables analyzed. This sug gests that, like the females, the males were relatively unaffected by imipramine treatment. Those effects ob served were regarding interest, rather than frequency of intercourse, or problems with ejaculation. None of the instruments, however, specifically inquired about difficulty achieving or maintaining an erection, the more typical complaint of males receiving acute tricyclic treat ment. The relationship between loss of libido as mea sured by the SCL-90, and higher HRSD-16 scores for the men treated with imipramine, further supports the notion that the correlation between decreased interest in sex may not be a result of a drug-related physiologi cal response, but instead a result of subclinical symp toms of depression. Note that the average age of the men was 40 with a standard deviation of 11 years. This leaves few over the age of 50 in the analysis. It is possi ble that older men may experience greater sexual dys function; however, we speculate that in a larger sam ple of comparably aged men, a similar response may be observed in those not treated with imipramine.
In contrast to previous fIndings regarding the acute effect of tricyclic antidepressants on sexual functioning, our analysis suggests that imipramine maintenance therapy may not adversely affect the level of sexual in terest or pleasure. If anything, it would appear that it is the presence of low-grade depressive symptoms, ir respective of method of treatment, which is associated with diminished libido or decreased sexual pleasure. Given the very substantial benefit observed in the over all trial for maintenance pharmacotherapy (see ), we conclude that the cost/benefit ratio of NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 impaired sexual functioning and pleasure versus the efficacy of maintenance therapy should alleviate fears and misconceptions about the prolonged use of tricy clic antidepressant medications.
